As of 14 Oct 2026, Odyssey has raised $213M across 1 verified round on record; latest: $213 million Series D, announced 10 Sep 2025.
Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients.
odysseytx.comLinkedInBostonBiotech
1 source
OrbiMed is identified as Odyssey’s earlier biggest backer, but is not named as participating in this round. No lead investor is identified.
Published by hand (fiercebiotech.com): "Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D after abandoning plans to go public this summer.": Checked by hand: Fierce Biotech states the $213M Series D.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series D [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $213M | 2025-09-10 | not stated | No recent discussion |
1 source [ VERIFIED · CORRECTED ] read against 1 source
OrbiMed is identified as Odyssey’s earlier biggest backer, but is not named as participating in this round. No lead investor is identified. Published by hand (fiercebiotech.com): "Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D after abandoning plans to go public this summer.": Checked by hand: Fierce Biotech states the $213M Series D. | ||||